[go: up one dir, main page]

WO2011006040A3 - Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases - Google Patents

Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases Download PDF

Info

Publication number
WO2011006040A3
WO2011006040A3 PCT/US2010/041481 US2010041481W WO2011006040A3 WO 2011006040 A3 WO2011006040 A3 WO 2011006040A3 US 2010041481 W US2010041481 W US 2010041481W WO 2011006040 A3 WO2011006040 A3 WO 2011006040A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
kidney disease
pkd
polycystic kidney
treating polycystic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/041481
Other languages
French (fr)
Other versions
WO2011006040A2 (en
Inventor
Rong Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stowers Institute for Medical Research
Original Assignee
Stowers Institute for Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stowers Institute for Medical Research filed Critical Stowers Institute for Medical Research
Priority to US13/382,978 priority Critical patent/US20120122787A1/en
Publication of WO2011006040A2 publication Critical patent/WO2011006040A2/en
Anticipated expiration legal-status Critical
Publication of WO2011006040A3 publication Critical patent/WO2011006040A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is directed to, inter alia, methods of treating or ameliorating an effect of a polycystic disease. This method include administering to a patient in need thereof an amount of a modulator of a histone deacetylase (HDAC) pathway, which is sufficient to treat or ameliorate an effect of a polycystic disease, particularly a polycystic kidney disease.
PCT/US2010/041481 2009-07-10 2010-07-09 Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases Ceased WO2011006040A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/382,978 US20120122787A1 (en) 2009-07-10 2010-07-09 Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27062609P 2009-07-10 2009-07-10
US61/270,626 2009-07-10

Publications (2)

Publication Number Publication Date
WO2011006040A2 WO2011006040A2 (en) 2011-01-13
WO2011006040A3 true WO2011006040A3 (en) 2012-05-31

Family

ID=43429848

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/041481 Ceased WO2011006040A2 (en) 2009-07-10 2010-07-09 Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases

Country Status (1)

Country Link
WO (1) WO2011006040A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013079560A1 (en) 2011-11-29 2013-06-06 Westfälische Wilhelms-Universität Münster Genetic marker for polycystic ovary syndrome (pcos)
EP2819691A1 (en) 2012-03-02 2015-01-07 Erasmus University Medical Center Rotterdam Methods for activating retrovirus in latent infected cells, and compounds for use therein
US9670236B2 (en) 2012-10-31 2017-06-06 University of Pittsburgh—of the Commonwealth System of Higher Education Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury
WO2015061684A1 (en) 2013-10-24 2015-04-30 Mayo Foundation For Medical Education And Research Treatment of polycystic diseases with an hdac6 inhibitor
WO2019190214A1 (en) * 2018-03-28 2019-10-03 크리스탈지노믹스(주) Pharmaceutical composition for prevention or treatment of fibrosis
KR101987591B1 (en) * 2018-08-06 2019-06-10 국립해양생물자원관 Nucleic acids aptamer binding specifically to Ingenol mebutate
US11360080B2 (en) * 2018-08-17 2022-06-14 National Health Research Institutes AhR-ROR-γt complex as a biomarker and therapeutic target for autoimmune disease and IL-17A-associated disease
EP4292591A1 (en) * 2022-06-14 2023-12-20 Universitätsmedizin Greifswald Compounds for use in the treatment of kidney diseases
CN119896665A (en) * 2025-04-01 2025-04-29 吉林大学第一医院 Application of daphnetin in the treatment of drug-resistant ovarian cancer

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
US20050159347A1 (en) * 2001-04-24 2005-07-21 Dimartino Jorge F. Methods for treating hematological disorders through inhibition of DNA methylation and histone deacetylase
US7250514B1 (en) * 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20070248590A1 (en) * 2005-12-02 2007-10-25 Sirtris Pharmaceuticals, Inc. Modulators of CDC2-like kinases (CLKS) and methods of use thereof
US7399884B2 (en) * 2002-10-08 2008-07-15 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7488754B2 (en) * 2002-04-05 2009-02-10 Wyeth Method for the treatment of polycystic kidney disease

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050159347A1 (en) * 2001-04-24 2005-07-21 Dimartino Jorge F. Methods for treating hematological disorders through inhibition of DNA methylation and histone deacetylase
US7488754B2 (en) * 2002-04-05 2009-02-10 Wyeth Method for the treatment of polycystic kidney disease
US7399884B2 (en) * 2002-10-08 2008-07-15 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) * 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
US20070248590A1 (en) * 2005-12-02 2007-10-25 Sirtris Pharmaceuticals, Inc. Modulators of CDC2-like kinases (CLKS) and methods of use thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Conversations with Oncology Investigators.", CONVERSATIONS WITH ONCOLOGY INVESTIGATORS., 2008, pages 3, Retrieved from the Internet <URL:http:l/www.hematologiconcologyupdate.com/2008/2/gore.asp> [retrieved on 20120326] *
SAITO ET AL.: "A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.", PROC NATL ACAD SCI USA, vol. 96, no. 8, 1999, pages 4592 - 4597, XP002158228, doi:10.1073/pnas.96.8.4592 *
SHARMA ET AL.: "The homeodomain protein Cux1 interacts with Grg4 to repress p27 kipl expression during kidney development.", GENE, 15 June 2009 (2009-06-15) *
VAN BODEGOM ET AL.: "The polycystic kidney disease-1 gene is a target for p53-mediated transcriptional repression.", J BIOL CHEM., vol. 281, no. 42, 2006, pages 31234 - 44 *
WIKIPEDIA.: "Autosomal dominant polycystic kidney", AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY, 14 June 2009 (2009-06-14), pages 1, Retrieved from the Internet <URL:http:l/en.wikipedia.org/wlindex.php?title=Autosomaldominant_polycystickidney&oldid=296269528> *

Also Published As

Publication number Publication date
WO2011006040A2 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
WO2011006040A3 (en) Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases
WO2012068109A3 (en) Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
WO2008000512A3 (en) Method for identifying crmp modulators
WO2010040112A3 (en) Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
WO2011091213A3 (en) Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
WO2007143600A3 (en) Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
WO2008132234A3 (en) Rna antagonist compounds for the modulation of beta-catenin
WO2012062925A3 (en) Compounds and methods for treating pain
WO2010129746A3 (en) Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
WO2011017030A3 (en) Treatment of macrophage-related disorders
WO2011084455A3 (en) Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
WO2011011700A3 (en) Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
WO2011150007A3 (en) Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
WO2011103528A3 (en) Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
WO2009124330A3 (en) Treatment of tumors
WO2012047956A3 (en) Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
WO2011097582A3 (en) Treatment of arachidonate 12-lipoxygenase, 12r type (alox12b) related diseases by inhibition of natural antisense transcript to alox12b
WO2011017516A3 (en) Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
AU2011322715A8 (en) Treatment of MeCP2-associated disorders
WO2009071082A3 (en) Rna antagonist compounds for the modulation of pik3ca expression
WO2013039956A3 (en) Compositions and methods for treating mood disorders
WO2009045543A8 (en) Treatment of conditions related to shock
WO2011127048A3 (en) NON-HORMONAL STEROID MODULATORS OF NF-ĸB FOR TREATMENT OF DISEASE
WO2008140708A8 (en) Use of hdac inhibitors for treatment of cardiac rhythm disorders
WO2012145737A8 (en) Fatty acid amide hydrolase inhibitors for treating pain

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10797893

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13382978

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 10797893

Country of ref document: EP

Kind code of ref document: A2